These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3827471)

  • 21. Antithrombin III transfusion in patients with hepatic cirrhosis.
    Schipper HG; ten Cate JW
    Br J Haematol; 1982 Sep; 52(1):25-33. PubMed ID: 7115627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circadian rhythms of fibrinogen and antithrombin III in liver cirrhosis.
    Pasqualetti P; Casale R
    Riv Eur Sci Med Farmacol; 1995; 17(4):125-9. PubMed ID: 8545565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in levels of blood coagulation inhibitors in cirrhosis. Prospective study in 33 patients].
    Dumontier I; Alhenc-Gelas M; Chatellier G; Brenet P; Aiach M; Petite JP
    Gastroenterol Clin Biol; 1992; 16(2):120-5. PubMed ID: 1314744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Turnover study of prothrombin, antithrombin III and fibrinogen in patients with liver cirrhosis.
    Saitoh H; Kobayashi N; Maekawa T
    Nihon Ketsueki Gakkai Zasshi; 1986 Sep; 49(6):1263-74. PubMed ID: 3811789
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunologic measurement of antithrombin III-heparin cofactor and alpha2 macroglobulin in disseminated intravascular coagulation and hepatic failure coagulopathy.
    Damus PS; Wallace GA
    Thromb Res; 1975 Jan; 6(1):27-38. PubMed ID: 46627
    [No Abstract]   [Full Text] [Related]  

  • 26. Antithrombin III contribution to cholestasis differential diagnosis: its correlation with one stage prothrombin time and factor V.
    Monasterio J; Juncá J; Torras J; Clotet B; Cervantes M; Alloza JL; Triginer J
    Clin Lab Haematol; 1980; 2(3):185-90. PubMed ID: 7428310
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bovine or human thrombin in amidolytic at III assays. Influence of heparin cofactor II.
    Conard J; Bara L; Horellou MH; Samama MM
    Thromb Res; 1986 Mar; 41(6):873-8. PubMed ID: 3754659
    [No Abstract]   [Full Text] [Related]  

  • 28. [At II in liver diseases. Comparison between immunological determination and that with chromogenic substrate].
    Carmignoto F; Schivo P; Zotti S; Ceriotti G
    Arch Sci Med (Torino); 1980; 137(3):467-70. PubMed ID: 6786256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The value of coagulation factors in severity categorization of hepatitis B-related liver cirrhosis].
    Li Q; Wang BE; Cong YL; Jia JD; Yin ZJ; Qian LX; Ma H
    Zhonghua Nei Ke Za Zhi; 2005 Mar; 44(3):188-90. PubMed ID: 15840257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.
    Rodzynek JJ; Urbain D; Leautaud P; Wettendorff P; Delcourt A
    Gut; 1984 Oct; 25(10):1050-6. PubMed ID: 6479679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism.
    Kawanaka H; Akahoshi T; Kinjo N; Konishi K; Yoshida D; Anegawa G; Yamaguchi S; Uehara H; Hashimoto N; Tsutsumi N; Tomikawa M; Maehara Y
    Ann Surg; 2010 Jan; 251(1):76-83. PubMed ID: 19864937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progressive antithrombin activity and the concentration of three thrombin inhibitors in liver cirrhosis.
    Boneu B; Sie P; Caranobe C; Cassigneul J; Pascal J
    Thromb Haemost; 1982 Feb; 47(1):78. PubMed ID: 7071809
    [No Abstract]   [Full Text] [Related]  

  • 33. Antithrombotic and antifibrinolytic effects of antithrombin III replacement in liver cirrhosis.
    Carmassi F; De Negri F; Morale M; Ferrini L
    Lancet; 1997 Apr; 349(9058):1069. PubMed ID: 9107249
    [No Abstract]   [Full Text] [Related]  

  • 34. [Antithrombin III: the correlation structure-function in healthy people and in cirrhotic patients (author's transl)].
    Vicente JM; Díaz Cremades JM; Borrell M; Felez J; Gimferrer E; Pujol N; Domingo A; Rutllant ML
    Sangre (Barc); 1978; 23(5):544-53. PubMed ID: 368998
    [No Abstract]   [Full Text] [Related]  

  • 35. Decreased protein C function predicts mortality in patients with cirrhosis.
    Patil AG; Bihari C; Shewade HD; Nigam N; Sarin SK
    Int J Lab Hematol; 2018 Aug; 40(4):466-472. PubMed ID: 29704446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The determination of antithrombin III by radioimmunoassay and its clinical application.
    Chan V; Chan TK; Wong V; Tso SC; Todd D
    Br J Haematol; 1979 Apr; 41(4):563-72. PubMed ID: 435403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemostasis activation in patients with liver cirrhosis.
    Vukovich T; Teufelsbauer H; Fritzer M; Kreuzer S; Knoflach P
    Thromb Res; 1995 Feb; 77(3):271-8. PubMed ID: 7740519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coagulation and fibrinolysis in orthotopic liver transplantation: role of the recipient's disease and use of antithrombin III concentrates. S. Orsola Working Group on Liver Transplantation.
    Palareti G; Legnani C; Maccaferri M; Gozzetti G; Mazziotti A; Martinelli G; Zanello M; Sama C; Coccheri S
    Haemostasis; 1991; 21(2):68-76. PubMed ID: 1959800
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of the biological activity of antithrombin III in patients with hepatic cirrhosis.
    Matsuo T; Matsuo C; Matsuo O
    Clin Chim Acta; 1984 Jul; 140(2):125-32. PubMed ID: 6467606
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased plasma antithrombin III level in hyperlipidemic subjects.
    Cucuianu MP; Cristea A; Roman S; Missits I
    Clin Chim Acta; 1981 Mar; 110(2-3):147-55. PubMed ID: 7226527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.